Diego, CA) [32] . Animals were selected for treatment when the longest dimension of the subcutaneous 129 tumors was between 7 to 10 mm in length. The size of the tumors was measured on the day of treatment 130 using a caliper. 131 132 In vivo TPT experiment design 133 To evaluate the efficacy of Cet-IR700DX based NIR TPT via interstitial and superficial irradiation, mice 134 with bilateral subcutaneous tumors were first separated into low and high TPT dosimetry groups herein 135 referred to as treatment groups, with sample size starting at n = 5 per group. Each mouse was injected 136 with 100 µg of Cet-IR700DX in PBS intravenously (IV) 24 hours prior to light irradiation. The day of IV 137 injection was considered t=0h. At 24 hours after IV injection (t= 24h), the right flank tumor of each 138 mouse was exposed prior to treatment through an incision on the skin. For interstitial irradiation, the 139 right flank tumors of mice in the low and high dosimetry groups were then irradiated interstitially at 100 140 J/cm and 300 J/cm doses respectively with a 690nm wavelength light source at 400 mW/cm fixed laser 141 power output. For superficial irradiation, the right flank tumors of mice in the low and high dosimetry 142 groups were then irradiated superficially at 50 J/cm 2 and 250 J/cm 2 fluences respectively with a 690nm 143 wavelength light source at 150 mW/cm 2 fixed laser power output. Immediately after irradiation, the skin incision was sutured to cover the tumor prior to fluorescence 146 imaging.
148
The fluorescence imaging and fluorescence intensity data of GFP were captured before IV to 149 establish the baseline (at t=0h), after IV and prior to TPT (at t=24 h) to detect and confirm drug 150 localization in tumors, immediately after TPT, and at termination (t=72 h), 3 days after TPT; for a total 151 of four imaging time points. The mice were sacrificed at termination (t = 72 h), after their tumors were 152 excised post imaging, and harvested for further analysis and histological processing. A total of 30 male,6 week old, athymic (nu/nu) BALB/c mice (Anticancer, Inc., San Diego, CA) were 164 used in this project. They were maintained in a barrier facility on high efficiency particulate air-filtered 165 racks. In general, mice were anesthetized during all experimental procedures causing more than 166 slight pain or distress. A toe pinch was used to ensure adequate anesthesia prior to execution of 167 surgical, irradiation, and imaging procedures. Anesthesia depth was monitored by measuring 168 respiratory rate, heart rate, tail pinch, corneal and pedal reflexes, blood pressure, and body 169 temperature. Anesthesia was achieved by (1) Isoflurane inhalation for procedures of very short Page | 8 duration, i.e. 5-20 minutes, or by (2) an intramuscular injection into the muscle of the hind limb of a 171 mixture of 50% ketamine, 38% xylazine and 12% acepromazine maleate for the longer term surgical 172 and imaging procedures (25-40 minutes). Whenever the pain was prolonged and could not be 173 avoided, the animal was euthanized as soon as possible.
175
To facilitate the execution of procedures and to minimize injury, anesthetized mice were constrained 176 with soft limb restraints during subcutaneous injection, irradiation, and imaging procedures. During At the completion of the observational period (at termination, t=72h), all 30 mice were euthanized 185 while still under anesthesia (after last imaging and tumors excision) in a dedicated vivarium CO2 186 euthanasia chamber, supplied by compressed gas cylinders. Gas flow was maintained for 2 minutes 187 after apparent clinical death; and death was verified before removing animals from the chamber. In vivo fluorescence imaging 190 The whole animal fluorescence imaging and fluorescence intensity data of GFP were captured using 191 the MAESTRO CRI In-vivo imaging system (Cri, Woburn, MA, USA) and software (version 2.10.0).
193
The GFP fluorescence signal was detected using the Maestro pre-set blue filter set with a 455-nm 194 excitation filter (435 to 480 nm range), and a 490 nm long-pass emission filter in 10 nm step imaging Page | 9 increments from 500 to 800 nm, at 350 ms fixed exposure time, and a pixel binning of 1x1. The resulting 196 image containing the collective spectral fluorescence data from each wavelength within the 500 to 800 197 nm range was then unmixed using the Maestro software, to isolate the GFP emission wavelength 198 containing the fluorescence intensity data of interest.
200
The 700DX dye fluorescence signal was detected using the Maestro pre-set red filter set with a 635-201 nm excitation filter (616 to 661 nm range), and a 675 nm long-pass emission filter in 10 nm step 202 imaging increments from 670 to 900 nm, at 700 ms fixed exposure time, and a pixel binning of 1x1.
203
Using the same method for above for GFP, the fluorescence intensity data for IR700DX was collected 204 from the channel corresponding to the IR700DX emission wavelength of 700 nm.
206
In vivo fluorescence data acquisition 207 GFP intensity data were extracted from the resulting images using the regions of interest (ROI) method.
208
The Maestro software used pixel counts to depict fluorescence intensity. The GFP fluorescence intensity measurements of the left control and right treated tumors of each 242 treatment group were averaged, and the mean intensities were plotted as relative intensity ± standard 243 deviation of the mean intensity.
244
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Histological and immunohistochemical analysis 246 After the mice were sacrificed at t=72h, the subcutaneous tumors were excised and fixed in formalin 247 for 24 hours. After formalin fixation, the tumors were dehydrated, paraffin-embedded, and cut in 5 µm 248 sections that were then placed on glass slides for GFP immunohistochemical staining and standard 249 Hematoxylin and Eosin (H&E) histological staining. 
Results
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Prior to TPT treatment, baseline was established by untreated (conjugate and irradiation naïve) healthy 271 animals weighing on average 20 grams, and whose subcutaneous tumors have reached 7-10 nm in 272 length. The six animals originally allocated per group prior to treatment were included in the qualitative 273 and quantitative data analysis reported herein. (Fig 3) . After interstitial TPT treatment, there was visible reduction of GFP fluorescence on the right flank tumors 290 of both treatment groups, with less visible fluorescence intensity observed in the tumor of the 300 J/cm 291 treatment group compared to the 100 J/cm treatment group (Fig 4) . Seventy-two hours after treatment, 292 an increase in GFP fluorescence signal was visible on the right flank tumor of both treatment groups; 293 although is noticeably less than the GFP fluorescence signal at baseline and before TPT. before intravenous (IV) injection of Cet-IR700DX conjugate t = 0h, 2) after IV injection and prior to 321 photo therapy (PT) t = 24 hours, 3) immediately after PT, 4) at termination, 72 hours after PT, t = 72 322 hours.
324
In addition, statistical analysis via the One-Factor ANOVA with repeated measures test showed that 325 there was a significant difference in GFP fluorescence intensity levels among the four time points in 326 both treatment groups (50J/cm 2 : F(0.0001)<0.05; 250J/cm 2 : F(0.022)<0.05). The difference in cytotoxic effects between the two groups immediately after TPT was not significant 337 (t(0.341) > 0.05, post-hoc Welch t-test) according to a Welch One Way ANOVA test. However, the 338 difference in recovery levels 72 hours post treatment (72 HRS) between the two groups as indicated 339 by the increase in the relative GFP fluorescence intensity level (1% for 50J/cm 2 group and 44% for 340 250 J/cm 2 group), was statistically significant (t(0.001) < 0.05, Welch t-test). The slight variability in the fluorescence intensity values between baseline and before TPT time points 369 in both treatment groups was not significant (100J/cm: p(0.3530) > 0.05 and 300 J/cm: p(0.9960) > 370 0.05, Tukey-Kramer test).
372
No adverse events were observed in each experimental group during or after TPT treatment. There was more significant damage observed in tumors treated at the 50J/cm 2 light dose (Fig 7, right) 386 compared to those treated at the 250 J/cm 2 dose (Fig 8, right) . The H&E stained histological tissue 387 sample of a treated tumor depicted in Fig 8 (right image) for the 250 J/cm 2 treatment group, shows the 388 presence of viable cells, while the tissue sample of the 50 J/cm 2 treatment group (Fig 7) shows mostly 389 damaged cells (elongated nuclei fragments and loss of cytoplasmic membrane), and detached ECM 390 compared to control. In tumor samples irradiated interstitially (Figs 9 and 10) , there was more significant damage observed 405 in tumors treated at the high 300J/cm light dose (Fig 10) compared to those treated at the low 100 J/cm 406 dose (Fig 9) . The effectiveness of targeted photo therapy administered superficially has been demonstrated to 443 selectively induce some cytotoxicity in different types of cancers in vitro and in vivo immediately after 444 treatment, and more complete cytotoxicity in the long-term after repeated irradiations [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . 445 446 In the present study, we investigated the effectiveness of both superficial and interstitial administration Analogous to other TPT studies, acute cytotoxicity was achieved immediately after treatment under 459 both light delivery strategies; GFP fluorescence intensity decreased immediately after TPT by 81% 460 (p<0.05) and by 91% (p<0.05) in tumors treated superficially at 50 J/cm 2 and 250 J/cm 2 respectively 461 compared to controls (Fig 3) , and by 69% (p<0.05) and 84% (p<0.05) in tumors treated interstitially at 462 100 J/cm and 300 J/cm respectively compared to controls (Fig 4) . Preliminarily, these data indicate 463 that superficial TPT was more effective in eliciting acute cytotoxicity as indicated by higher signal loss 464 percentages, compared to interstitial TPT. However, 72 hours post treatment, GFP fluorescence 465 signal recovery was observed in both light dose of the superficial TPT treatment groups, and in the Page | 20 higher dose of the interstitial TPT treatment group. These results support the data of other TPT 467 studies that demonstrated that a single TPT treatment did not inhibit cancer recurrence, and that 468 repeated treatments were necessary to kill almost all cancer cells in the long-term [41] [42] [43] .
470
While the higher light dose resulted in higher GFP signal loss in both light delivery strategies 471 immediately after treatment, the interstitial TPT strategy resulted in less GFP fluorescence signal 472 recovery 72 hours post irradiation and thus more complete cytotoxic effect (0% recovery at 100 J/cm, 473 and 11% recovery at 300 J/cm), compared to superficial TPT (1% and 44% recovery at 50J/cm 2 and 474 250 J/cm 2 respectively). These signal recovery data were not statistically significant intra groups 475 (p>0.05 among low and high doses), but were statistically significant inter groups (p<0.05 between 476 interstitial and superficial treatments).
478
These data demonstrated that interstitial TPT was more effective in achieving long-term cytotoxicity 479 as indicated by lower signal recovery 72 hours post treatment (less viable cells present) compared to 480 superficial TPT. In addition, these data demonstrated that better long-term cytotoxicity was achieved 481 at lower light doses in both light delivery strategies (0% and 1% signal recovery at 100 J/cm 482 interstitially and 50 J/cm 2 superficially, respectively). This demonstrated that interstitial illumination elicited more complete cytotoxicity compared to 492 superficial illumination.
494
Damage to normal tissue components such as muscle, skin, blood vessels and adipose tissue however 495 was not observed (Fig 11) ; demonstrating the selectivity of Cet-IR700DX based NIR-TPT to tumor cells While male mice were used in the study to reduce cost and use of animals, it could have presented 501 bias in the results. A study including both male and female mice will be conducted in the future to 502 account for sex as a possible source of bias. Furthermore, a study using a more physiologically relevant 503 animal model, such as an orthotopic pancreatic cancer mouse model, will be conducted to confirm the 504 results obtained in this study. Overall, Cetuximab-IR700DX based near infra-red targeted phototherapy was effective in inducing 508 selective killing of pancreatic cancer cells in vivo in a subcutaneous xenograft mouse model, 509 especially at the low light dose. Cetuximab-IR700DX based TPT administered interstitially however, 510 was more effective at inducing long-term selective cell damage, as demonstrated by the lower GFP 511 fluorescence signal recovery at both dosimetries and more tissue damage present in histological 512 tissue samples of treated tumors, compared to superficial TPT. Interstitial TPT thus, could be a better 513 method to achieve more complete cytotoxicity after a single treatment, compared to achieving 514 complete cytotoxicity after repeated treatments; which can lead to therapy induced resistance in 515 treated tumors.
While these results are promising, further studies are needed to determine the optimal light delivery 518 strategy, TPT conjugate, and light dose combination that will result in maximum cytotoxicity and long-519 term prevention of cancer recurrence and metastasis. 
